A Study of ABM-1310 in Patients With BRAF V600-Mutant Relapsed and Drug Resistant Primary Malignant Brain Tumors

NCT05892653 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

15

Enrollment

INDUSTRY

Sponsor class

Stopped Adjustment of the applicant's research and development strategy

Conditions

Primary Malignant Brain Tumor

Interventions

DRUG: ABM-1310

Sponsor

ABM Therapeutics Shanghai Company Limited